Efficacy of Bypassing Agents in Patients With Hemophilia and Inhibitors: A Systematic Review and Meta-Analysis

Clinical Therapeutics

Volumn 34, Issue 2, 2012, Pages 434-445

  Zhou, Zheng Yi ^a   Hay, Joel W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

APCC; Efficacy; Hemophilia; Inhibitor; Meta analysis; RFVIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

DISEASE SEVERITY; DRUG EFFICACY; EVALUATION AND FOLLOW UP; HEMARTHROSIS; HEMOPHILIA; HUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ANTIBODIES; BLOOD COAGULATION FACTORS; FACTOR IX; FACTOR VIIA; FACTOR VIII; HEMOPHILIA A; HUMANS; RECOMBINANT PROTEINS;

EID: 84863016473     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.01.001     Document Type: Review

References (39)

1. Iorio A., Marchesini E., Marcucci M., et al. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011, 9. CD003429.
2. Manco-Johnson M.J., Abshire T.C., Shapiro A.D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007, 357:535-544.
3. Ehrenforth S., Kreuz W., Scharrer I., et al. Incidence of development of Factor VIII and Factor IX inhibitors in haemophiliacs. Lancet 1992, 339:594-598.
4. Hay C.R., Ludlam C.A., Colvin B.T., et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A. Thrombosis Haemostasis 1998, 79:762-766. UK Haemophilia Centre Directors Organisation.
5. DiMichele D.M. Inhibitors in haemophilia: a primer. Haemophilia 2000, 6(Suppl 1):38-40.
6. Ho A.Y., Height S.E., Smith M.P. Immune tolerance therapy for haemophilia. Drugs 2000, 60:547-554.
7. Kempton C.L., White G.C. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009, 113:11-17.
8. Hay C.R., Brown S., Collins P.W., et al. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation. Br J Haematol 2006, 133:591-605.
9. Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009, 15:3-10.
10. FEIBA VH [prescribing information] 2005, Baxter Healthcare Corporation, Westlake Village, Calif.
11. Teitel J., Berntorp E., Collins P., et al. A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. Haemophilia 2007, 13:256-263.
12. Hilgartner M.W., Knatterud G.L. The use of factor eight inhibitor by-passing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophiliacs with inhibitors. Blood 1983, 61:36-40.
13. Key N.S., Aledort L.M., Beardsley D., et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998, 80:912-918.
14. Négrier C., Goudemand J., Sultan Y., et al. Multicenter retrospective study on the utilization of FEIBA in France in patients with Factor VIII and Factor IX inhibitors. Thromb Haemost 1997, 77:1113-1119. French Factor Eight Bypassing Activity (FEIBA) Study Group.
15. Astermark J., Donfield S.M., DiMichele D.M., et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109:546-551.
16. Young G., Shafer F.E., Rojas P., Seremetis S. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison. Haemophilia 2008, 14:287-294.
17. Iorio A., Matino D., D'Amico R., Makris M. Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2010, 8. CD004449.
18. Treur M.J., McCracken F., Heeg B., et al. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression. Haemophilia 2009, 15:420-436.
19. Turecek P.L., Varadi K., Gritsch H., et al. Factor Xa and prothrombin: mechanism of action of FEIBA. Vox Sang 1999, 77(Suppl 1):72-79.
20. Lundblad R.L., Bergstrom J., De Vreker R., et al. Measurement of active coagulation factors in Autoplex-T with colorimetric active site-specific assay technology. Thromb Haemost 1998, 80:811-815.
21. Lilienfeld D.E., Stolley P.D. Foundations of Epidemiology 1994, Oxford University Press, Oxford, UK. 3rd ed.
22. Laird N.M., Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care 1990, 6:5-30.
23. Egger M., Smith G.D., Altman D. Systematic Reviews in Health Care: Meta-Analysis in Context 2001, BMJ Books, Boston, Mass. 2nd ed.
24. Kavakli K., Makris M., Zulfikar B., et al. Home treatment of haemarthroses using a single dose regimen of recombinant activated Factor VII in patients with haemophilia and inhibitors. A multi-centre, randomised, double-blind, cross-over trial. Thromb Haemost 2006, 95:600-605.
25. Santagostino E., Mancuso M.E., Rocino A., et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthroses in hemophiliacs with inhibitors. J Thromb Haemost 2006, 4:367-371.
26. Lusher J.M., Roberts H.R., Davignon G., et al. A randomized, double-blind comparison of two dosage levels of recombinant Factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia 1998, 4:790-798. rFVIIa Study Group.
27. Sjamsoedin L.J., Heijnen L., Mauser-Bunschoten E.P., et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to Factor VIII. A double-blind clinical trial. N Engl J Med 1981, 305:717-721.
28. Hilgartner M., Aledort L., Andes A., Gill J. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990, 30:626-630. FEIBA Study Group.
29. Holme P.A., Glomstein A., Grønhaug S., Tjønnfjord G.E. Home treatment with bypassing products in inhibitor patients: a 7.5-year experience. Haemophilia 2009, 15:727-732.
30. Négrier C. FEIBA VH in home treatment-a 3-year prospective experience. Haemophilia 1998, 4:238. Abstract 330.
31. Bech R.M. Recombinant Factor VIIa in joint and muscle bleeding episodes. Haemostasis 1996, 26(Suppl 1):135-138.
32. Laurian Y., Goudemand J., Negrier C., et al. Use of recombinant avtivated Factor VII as first-line therapy for bleeding episodes in haemophiliacs with Factor VIII or IX inhibitors (NOSEPAC study). Blood Coagul Fibrinolysis 1998, 9(Suppl 1):S155-S156.
33. Santagostino E., Gringeri A., Mannucci P.M. Home treatment with recombinant activated Factor VII in patients with Factor VIII inhibitors: the advantages of early intervention. Br J Haematol 1999, 104:22-26.
34. Chuansumrit A., Isarangkura P., Angchaisuksiri P., et al. Controlling acute bleeding episodes with recombinant Factor VIIa in haemophiliacs with inhibitor: continuous infusion and bolus injection. Haemophilia 2000, 6:61-65.
35. Shapiro A.D. American experience with home use of NovoSeven: recombinant Factor VIIa in hemophiliacs with inhibitors. Haemostasis 1996, 26(Suppl 1):143-149.
36. Dimichele D., Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006, 12:352-362.
37. Smejkal P., Brabec P., Matyskova M., et al. FEIBA in treatment of acute bleeding episodes in patients with haemophilia A and Factor VIII inhibitors: a retrospective survey in regional haemophilia centre. Haemophilia 2009, 15:743-751.
38. Knight C., Dano A.M., Kennedy-Martin T. Systematic review of efficacy of rFVIIa and aPCC treatment for hemophilia patients with inhibitors. Adv Ther 2009, 26:68-88.
39. Jones P. Haemophilia home therapy. Haemostasis 1992, 22:247-250.